Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEN1112 in Relapsed or Refractory Acute Myeloid Leukemia
NCT02353143Phase 1Terminated
- Sponsor
- Menarini Group
- Start
- Dec 2014
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of MEN1112 in acute myeloid leukemia (AML), sponsored by Menarini Group. Primary endpoints: Dose Limiting Toxicity at 3 weeks and Maximum Tolerated Dose at 3 weeks. Started Dec 2014; status: terminated.
02
Drugs
MEN1112
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02353143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353143.